In a randomized clinical trial published in JAMA Psychiatry, a #GLP1 receptor agonist was assessed in patients with #Schizophrenia who were obese and had prediabetes
Our results suggest a correlation between AOM utilization and decreased likelihood of OSA development
Lertworapreecha, M., Chanasit, W., Nitipan, S., & Chamnankit, W
El efecto consistente de reduccin de la PCR que se observa tanto en el ensayo SELECT con semaglutida como en los ensayos en pacientes con ICFEp con semaglutida y tirzepatida apoyan esta mejora en la funcionalidad del tejido adiposo, que conllevara una disminucin del estado inflamatorio
The symptoms you have will depend on the types of dementia you have
Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior efficacy, while semaglutide achieves high efficacy with better tolerability